Finasteride is a Small Molecule owned by Organon, and is involved in 4 clinical trials, which were completed.

Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) responsible for prostate gland development and enlargement. Inhibition of Type II 5a-reductase prevents the peripheral conversion of testosterone into DHT, resulting in significant reduction of DHT concentrations in serum and tissue. In men with male pattern hair loss, the balding scalp contains miniaturised hair follicles and increased amounts of DHT. Finasteride inhibits a process responsible for miniaturisation of the scalp hair follicles, which can lead to reversal of the balding process.

The revenue for Finasteride is expected to reach a total of $2.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Finasteride NPV Report.

Finasteride is currently owned by Organon.

Finasteride Overview

Finasteride (Propecia) is a synthetic 4-azasteroid compound. It is formulated as film coated tablets, tablets for oral route of administration. Propecia is indicated for the treatment of male pattern hair loss (androgenetic alopecia) only in men.

Organon Overview

Organon is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It works in collaboration with pharmaceutical and biopharmaceutical companies to commercialize its products. Organon is headquartered in Jersey City, New Jersey, the US.

The company reported revenues of (US Dollars) US$6,304 million for the fiscal year ended December 2021 (FY2021), a decrease of 3.5% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 42.1% in FY2020. In FY2021, the company recorded a net margin of 21.4%, compared to a net margin of 33.1% in FY2020. The company reported revenues of US$1,537 million for the third quarter ended September 2022, a decrease of 3% over the previous quarter.

Quick View – Finasteride

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Finasteride
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
Key Companies
  • Sponsor Company: Organon
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.